---
document_datetime: 2024-03-01 15:45:57
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zinplava-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zinplava-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.702554
conversion_datetime: 2025-12-29 21:06:39.254545
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zinplava

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0037              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 14/12/2023                          | 26/01/2024                                  | SmPC and PL                      |           |
| IAIN/0039            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                          | 07/12/2023                          | 26/01/2024                                  | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            | PL                     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0038/G           | This was an application for a group of variations. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is | 22/06/2023 | 26/01/2024 | SmPC, Labelling and PL |                                   |
| PSUSA/10576 /202210 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/05/2023 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0035/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                       | 18/11/2022 | 24/03/2023 | Annex II and PL        |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0034             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                          | 22/09/2022   | n/a        |      |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------|
| PSUSA/10576 /202110 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/06/2022   | n/a        |      | PRAC Recommendation - maintenance |
| II/0031             | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                      | 22/04/2022   | n/a        |      |                                   |
| IA/0033             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                         | 08/04/2022   | 24/03/2023 | SmPC |                                   |
| IA/0032/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name | 18/02/2022   | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

|                     | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |                       |                                                                                                                                                                                                                                                                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0029              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                 | 22/07/2021 | 01/09/2021 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zinplava in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10576 /202010 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                              | 10/06/2021 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IA/0028             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                           | 10/03/2021 | n/a        |                       |                                                                                                                                                                                                                                                                        |
| IB/0026             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                           | 07/01/2021 | n/a        |                       |                                                                                                                                                                                                                                                                        |
| PSUSA/10576 /202004 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                              | 26/11/2020 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IA/0025             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                              | 30/10/2020 | n/a        |                       |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------|
| IB/0024   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/09/2020 | 01/09/2021 | SmPC, Annex II, Labelling and PL |           |
| II/0022   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/07/2020 | n/a        |                                  |           |
| IB/0021/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 18/05/2020 | n/a        |                                  | procedure |

<div style=\"page-break-after: always\"></div>

| PSUSA/10576 /201910   | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                                                   | 14/05/2020   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| PSUSA/10576 /201904   | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                                                   | 31/10/2019   | n/a   | PRAC Recommendation - maintenance   |
| PSUSA/10576 /201810   | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                                                                                                                                                                   | 16/05/2019   | n/a   | PRAC Recommendation - maintenance   |
| IB/0018               | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                 | 28/03/2019   | n/a   |                                     |
| IB/0017               | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                 | 22/02/2019   | n/a   |                                     |
| IB/0015/G             | This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 04/01/2019   | n/a   |                                     |
| II/0014               | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                        | 06/12/2018   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

| II/0013             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol   | 29/11/2018   | n/a        |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/10576 /201804 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                   | 31/10/2018   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0011              | Transfer of Marketing Authorisation                                                                                                                                                                                                                          | 23/05/2018   | 15/06/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10576 /201710 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                   | 17/05/2018   | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0009             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                          | 21/03/2018   | 15/06/2018 | SmPC                   |                                   |
| IB/0008             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                             | 28/02/2018   | n/a        |                        |                                   |
| PSUSA/10576 /201704 | Periodic Safety Update EU Single assessment - bezlotoxumab                                                                                                                                                                                                   | 30/11/2017   | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0006             | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete                                                   | 27/10/2017   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |      |            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------|
| IB/0005   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                | 18/10/2017 | n/a        |      |            |
| IB/0003   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                   | 04/09/2017 | 15/06/2018 | SmPC |            |
| IA/0004/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites manufacturer for batch release) | 31/08/2017 | n/a        |      | (excluding |
| N/0001    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                      | 30/03/2017 | 15/06/2018 | PL   |            |